Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Ipilimumab
Synonyms
Therapy Description

Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ipilimumab Yervoy BMS-734016 CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01450761 Phase III Cisplatin Ipilimumab Carboplatin Etoposide Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 13
NCT02339571 Phase II Sargramostim Nivolumab Ipilimumab Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Recruiting USA 0
NCT02279862 Phase II Ipilimumab Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 1
NCT01810016 Phase I Ipilimumab NY-ESO-1 peptide vaccine NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Terminated USA | AUS 0
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed USA | ROU | POL | NLD | LBN | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 10
NCT02678572 Phase III Dacarbazine Ipilimumab Melphalan Pembrolizumab Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Completed USA | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT 0
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Terminated USA 0
NCT02259231 Phase Ib/II Ipilimumab Nivolumab Omaveloxolone RTA 408 Capsules in Patients With Melanoma - REVEAL Completed USA 0
NCT01498978 Phase II Ipilimumab Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Completed USA 0
NCT01497808 Phase Ib/II Ipilimumab RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma Completed USA 0
NCT02703623 Phase II Ipilimumab Abiraterone + Apalutamide + Prednisone Cabazitaxel + Carboplatin A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO) Active, not recruiting USA 0
NCT01585194 Phase II Ipilimumab Nivolumab Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma Completed USA 0
NCT02812524 Phase I Ipilimumab Ipilimumab for Head and Neck Cancer Patients Active, not recruiting USA 0
NCT03445533 Phase III Ipilimumab IMO-2125 + Ipilimumab A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) Terminated USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | AUS 0
NCT04591431 Phase II Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) Active, not recruiting ITA 0
NCT02530463 Phase II Nivolumab Azacitidine Ipilimumab Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) Active, not recruiting USA 0
NCT02500797 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma Completed USA 0
NCT02032810 Phase I Panobinostat Ipilimumab Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Completed USA 0
NCT02158520 Phase II Ipilimumab Bevacizumab + Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Completed USA 0
NCT03110107 Phase Ib/II Ipilimumab BMS-986218 + Nivolumab BMS-986218 First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors Terminated USA | ROU | POL | NOR | NLD | ITA | ISR | FRA | FIN | ESP | DEU | CHE | CAN | BEL | AUS | ARG 1
NCT01950390 Phase II Ipilimumab Bevacizumab + Ipilimumab Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery Active, not recruiting USA 0
NCT04697576 Phase I Nivolumab Pembrolizumab Ipilimumab Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma Recruiting USA 0
NCT03690986 Phase I Ipilimumab Nivolumab Ipilimumab + Pepinemab Nivolumab + Pepinemab Pepinemab VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer Recruiting USA 0
NCT04323046 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Recruiting USA | ISR | CHE | AUS 0
NCT02054520 Phase II Ipilimumab Immunotherapy Study for Patients With Stage IV Melanoma Terminated USA 0
NCT02737475 Phase Ib/II Ipilimumab BMS-986178 Nivolumab Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors Completed USA | NLD | ITA | ISR | ESP | CAN 0
NCT01804465 Phase II Ipilimumab A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer Completed USA 0
NCT04093323 Phase II alphaDC1 + Celecoxib + Interferon alpha-2b + Rintatolimod Ipilimumab unspecified PD-L1 antibody unspecified PD-1 antibody Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma Recruiting USA 0
NCT02388906 Phase III Nivolumab Ipilimumab Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) Active, not recruiting USA | SWE | ROU | POL | NOR | NLD | ITA | IRL | HUN | GRC | GBR | FRA | FIN | ESP | CZE | CHE | CAN | BEL | AUT | AUS | ARG 4
NCT01820754 Phase II Cisplatin Ipilimumab Carboplatin Paclitaxel Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT04131621 Phase II Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) Unknown status DEU 0
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Completed USA | CAN 0
NCT02239900 Phase Ib/II Ipilimumab Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors Completed USA 0
NCT01449279 Phase I Ipilimumab Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy Completed USA 0
NCT02009397 Phase Ib/II Sargramostim Ipilimumab A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients Completed USA 0
NCT02519322 Phase II Ipilimumab Nivolumab Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma Completed USA 0
NCT02020070 Phase II Ipilimumab Degarelix Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy Active, not recruiting USA 0
NCT01950195 Phase I Ipilimumab SRS (Stereotactic Radiosurgery) Plus Ipilimumab Terminated USA 0
NCT01696045 Phase II Ipilimumab Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma Terminated USA | GBR | FRA | ESP | DNK | DEU | BEL 1
NCT02060188 Phase Ib/II Nivolumab Ipilimumab A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) Active, not recruiting USA | ITA | IRL | FRA | ESP | CAN | BEL | AUS 0
NCT02307149 Phase I Coxsackievirus A21 Ipilimumab Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma Completed USA 0
NCT02311920 Phase I Temozolomide Nivolumab Ipilimumab Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed USA 0
NCT02107755 Phase II Ipilimumab Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Completed USA 0
NCT02221739 Phase II Ipilimumab Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02538666 Phase III Ipilimumab Nivolumab A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) Completed USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG 11
NCT01896869 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Ipilimumab A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer Completed USA 0
NCT01688492 Phase Ib/II Abiraterone + Prednisone Ipilimumab Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA 0
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Terminated USA 0
NCT02506114 Phase II PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer Terminated USA 0
NCT04929041 Phase II Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Recruiting USA 0
NCT02498600 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT02496208 Phase I Ipilimumab Cabozantinib + Nivolumab Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Active, not recruiting USA 0
NCT01970527 Phase II Ipilimumab Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Terminated USA 0
NCT02731729 Phase II Ipilimumab Nivolumab Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy Completed USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Active, not recruiting USA 0
NCT01565837 Phase II Ipilimumab Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma Unknown status USA 0
NCT01740297 Phase Ib/II Ipilimumab Talimogene laherparepvec Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Completed USA | FRA | DEU 0
NCT02027935 Phase II Aldesleukin Cyclophosphamide Ipilimumab Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 Completed USA 0
NCT01621490 Phase I Ipilimumab Nivolumab PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) Completed USA | NLD | ESP 0
NCT03056599 Phase I Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Completed USA 0
NCT01176474 Phase I NY-ESO-1 peptide vaccine Ipilimumab Nivolumab A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Completed USA 0
NCT05074992 Phase II Ipilimumab A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma (NeAT Glio) Terminated GBR 0
NCT04635735 Phase Ib/II Ipilimumab Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma Terminated USA 0
NCT02113657 Phase II Ipilimumab T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer Completed USA 0
NCT03166397 Phase II Cyclophosphamide + Fludarabine Aldesleukin Nivolumab tumor infiltrating lymphocytes Ipilimumab Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Recruiting ISR 0
NCT05188118 Phase I Cabozantinib Nivolumab Everolimus Ipilimumab Lenvatinib Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma Recruiting USA 0
NCT04157985 Phase III Nivolumab Ipilimumab Pembrolizumab Atezolizumab Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting USA 0
NCT01689974 Phase II Ipilimumab Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma Terminated USA 0
NCT02467361 Phase Ib/II Nivolumab Pembrolizumab Ipilimumab Napabucasin A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers Completed USA 0
NCT02115243 Phase I Ipilimumab Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma Completed USA 0
NCT02210104 Phase I Ipilimumab Cyclophosphamide Adoptive Therapy Using Antigen-Specific CD4 T-Cells Withdrawn 0
NCT03033576 Phase II Ipilimumab Ipilimumab + Nivolumab Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01711515 Phase I Ipilimumab Cisplatin Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer Completed USA 0
NCT01274338 Phase III Ipilimumab Interferon alpha-2b Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Active, not recruiting USA | CAN 0
NCT02553642 Phase II Nivolumab Ipilimumab Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) Completed USA 0
NCT02385669 Phase Ib/II 6MHP vaccine Ipilimumab A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma Terminated USA 0
NCT01409174 Phase Ib/II Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Terminated USA 0
NCT03600155 Phase I Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT02097732 Phase II Ipilimumab Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery Terminated USA 0
NCT05401786 Phase II Cemiplimab Ipilimumab Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO) Recruiting NLD 0
NCT01708941 Phase II Interferon alpha-2b Ipilimumab Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01701674 Phase I Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Active, not recruiting USA 0
NCT03477864 Phase I Ipilimumab Cemiplimab + Ipilimumab Cemiplimab Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer Withdrawn 0
NCT01940809 Phase II Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Terminated USA 0
NCT02117362 Phase I Ipilimumab Belapectin Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Completed USA 0
NCT02452281 Phase Ib/II Vitespen Ipilimumab Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma Withdrawn USA 0
NCT01530984 Phase II Sargramostim Ipilimumab Ipilimumab and GMCSF Immunotherapy for Prostate Cancer Withdrawn USA 0
NCT02073123 Phase Ib/II Ipilimumab Indoximod Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma Completed USA 0
NCT03070392 Phase II Dacarbazine Ipilimumab Pembrolizumab Tebentafusp Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS 2
NCT01703507 Phase I Ipilimumab Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases Completed USA 0
NCT02089685 Phase Ib/II Ipilimumab Peginterferon alfa-2b Pembrolizumab Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) Completed 0
NCT03068455 Phase III Nivolumab Ipilimumab Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) Completed USA | ROU | POL | NZL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS 1


Additional content available in CKB BOOST